RoosterBio, Inc., a Frederick, MD-based human mesenchymal stem/stromal cell (hMSC) biomanufacturing company, raised in excess of $15m in an initial Series B financing.
The round was led by Dynamk Capital, with participation from existing and new investors. The Series B final round is expected to close with additional investors by the end of August, totaling approximately $22m raised.
The investment will be used to expand and scale the RoosterBio team as its customer base continues to grow internationally, while bolstering research and development for their cell and gene therapy solutions.
Led by Margot Connor, CEO, RoosterBio is a cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high-volume and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with engineered media systems.
FinSMEs
06/08/2019